Bis-PEG13-NHS ester is a non-cleavable 13-unit PEG linker that can be used to synthesize antibody-conjugated drugs (ADCs).
Structure of 2221949-00-2
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Bis-PEG13-NHS ester, a versatile bifunctional crosslinker, finds widespread use in biochemical and biotechnological applications. Here are four key applications presented with high perplexity and burstiness:
Protein Conjugation: Bis-PEG13-NHS ester plays a pivotal role in linking proteins and peptides to various molecules like fluorescent dyes, drugs, or other biomolecules. Through its reaction with primary amines on proteins, stable amide bonds are formed, essential for the creation of targeted drug delivery systems and the analysis of protein interactions within diverse research landscapes.
Surface Modification: The compound’s utility extends to the modification of material surfaces, including nanoparticles, microbeads, and biosensors, enhancing biocompatibility and enabling specific binding interactions. By establishing a PEGylated layer, non-specific binding is mitigated, amplifying surface stability and functionality. This application holds particular significance in the advancement of diagnostic devices and biomedical implants.
Bioconjugation: Serving as a versatile linker for bioconjugation, Bis-PEG13-NHS ester facilitates the connection of antibodies, enzymes, or other biomolecules to solid supports or other entities. This linking capability is instrumental in crafting high-sensitivity assays, such as ELISA and immunoassays, where precise interactions are paramount. The resulting conjugates find application in diagnostics, therapeutic monitoring, and various bioanalytical endeavors.
Pharmaceutical Development: In the realm of drug development, Bis-PEG13-NHS ester emerges as a crucial tool for enhancing the pharmacokinetics and solubility of therapeutic molecules. Through the conjugation of drugs to PEG chains, the compound boosts drug stability and reduces immunogenicity, ultimately enhancing therapeutic efficacy. This approach proves particularly beneficial in the creation of long-lasting biopharmaceuticals and in diminishing the frequency of drug administration.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00379 | Bis-PEG4-NHS ester | 1314378-11-4 | |
BADC-00380 | Bis-PEG3-NHS Ester | 1314378-16-9 | |
BADC-00924 | Bis-PEG7-NHS ester | 1334170-02-3 | |
BADC-00960 | Bis-PEG6-NHS ester | 1526718-98-8 | |
BADC-01080 | Bis-PEG17-NHS ester | 2221948-93-0 | |
BADC-01081 | Bis-PEG25-NHS ester | 2221948-96-3 | |
BADC-01082 | Bis-PEG21-NHS ester | 2221948-98-5 | |
BADC-01084 | Bis-PEG10-NHS ester | 2221949-02-4 | |
BADC-00381 | Bis-PEG2-NHS Ester | 65869-63-8 | |
BADC-00382 | Bis-PEG1-NHS ester | 65869-64-9 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.